tiprankstipranks
Verastem initiated with a Neutral at Mizuho
The Fly

Verastem initiated with a Neutral at Mizuho

Mizuho initiated coverage of Verastem with a Neutral rating and $2 price target. The analyst says the company’s valuation expansion rests on confirmation of an accelerated approval path for avutometinib plus defactinib as well as clinical evidence of avutometinib combinations to treat KRASG12C non-small-cell-lung-cancer. Given the "nearer term riskiness" of the KRASG12C programs and the longer time horizon to LGSOC filing, the firm thinks investors "have time before becoming involved in the shares."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on VSTM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles